08.08.26 -- Bioprocess Online Newsletter - Best Of July

EU GMP Annex 1 mandates a documented contamination control strategy, and FDA expectations are substantively equivalent. Let's look at why CDMOs are disproportionately exposed.

Researchers produced a panel of platform cell lines illustrating how glycoform selection can be made experimentally visible earlier in biologics development.

In this segment from the Bioprocess Online Live event, panelists answer the question, “What should developers be thinking about upstream to avoid downstream complications?”

Understand the manufacturing challenges where rapid cell expansion often conflicts with therapeutic secretion profiles, requiring sophisticated quality control and donor selection strategies.

High particle counts don’t always mean high risk. Identifying particle type and origin—not just quantity—avoids false alarms, protects timelines, and turns data into action.

Life Edit accelerates genomic medicine by comparing five editing modalities, engineering new enzymes, and rapidly pinpointing optimal strategies that boost feasibility, cut risk, and speed clinical progress.